Vectura leans into new role as inhalation CDMO post-asthma flop with plant expansion
Two years after its leading asthma therapy flopped in a Phase III study, the UK’s Vectura switched gears to focus on manufacturing inhalable drugs for other biopharma companies. Now, it’s doubling down on that manufacturing angle with a new expansion at its UK production facilities.
Vectura unveiled this week an expansion of its capabilities to handle and develop highly potent active pharmaceutical ingredients (API) at its headquarters in Chippenham, England. The project will include installing six new containment isolators, which will house development manufacturing equipment for dispensing, blending, co-milling, jet-milling, spray-drying and blister-fill packaging — turning the facility into a newly-modeled product development manufacturing lab.